Dendritic cell-derived exosomes may be a tool for cancer immunotherapy by converting tumor cells into immunogenic targets

Frontiers in Immunology

Volumn 6, Issue JAN, 2015, Pages

  Romagnoli, Graziela Gorete ^a   Zelante, Bruna Barbosa ^a   Toniolo, Patrícia Argenta ^a   Migliori, Isabella Katz ^a   Barbuto, José Alexandre M ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cancer immunotherapy; Dendritic cells; Exosomes; Immunomodulation; Tumor cell immunogenicity; Tumor immune response

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 6; INTERLEUKIN 7; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROSTAGLANDIN E2; STAT3 PROTEIN; TOLL LIKE RECEPTOR 2; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTATION; ARTICLE; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; DENDRITIC CELL; DENDRITIC CELL DERIVED EXOSOME; ENZYME LINKED IMMUNOSPOT ASSAY; EXOSOME; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; NONHUMAN; T LYMPHOCYTE ACTIVATION; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84926673841     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00692     Document Type: Article

References (51)

1. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature (1998) 392:245-52. doi: 10.1038/32588
2. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol (1991) 9:271-96. doi:10.1146/annurev.iy.09.040191.001415
3. Barbuto JA, Ensina LF, Neves AR, Bergami-Santos P, Leite KR, Marques R, et al. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol Immunother (2004) 53:1111-8. doi:10.1007/s00262-004-0551-7
4. Berzofsky JA, Terabe M, Oh S, Belyakov IM, Ahlers JD, Janik JE, et al. Progress on new vaccine strategies for the immunotherapy and prevention of cancer. J Clin Invest (2004) 113:1515-25. doi:10.1172/JCI21926
5. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate (1996) 29:371-80. doi:10.1002/(SICI)1097-0045(199612)29:6<371::AID-PROS5>3.3.CO;2-3
6. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med (1998) 4:328-32. doi:10.1038/nm0398-328
7. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer (2012) 12:265-77. doi:10.1038/nrc3258
8. Wang K, Zhou Q, Guo AL, Xu CR, An SJ, Wu YL. An autologous therapeutic dendritic cell vaccine transfected with total lung carcinoma RNA stimulates cytotoxic T lymphocyte responses against non-small cell lung cancer. Immunol Invest (2009) 38:665-80. doi:10.1080/08820130903070528
9. Baleeiro RB, Anselmo LB, Soares FA, Pinto CA, Ramos O, Gross JL, et al. High frequency of immature dendritic cells and altered in situ production of interleukin-4 and tumor necrosis factor-alpha in lung cancer. Cancer Immunol Immunother (2008) 57:1335-45. doi:10.1007/s00262-008-0468-7
10. Barbuto JA. Are dysfunctional monocyte-derived dendritic cells in cancer an explanation for cancer vaccine failures? Immunotherapy (2013) 5:105-7. doi:10.2217/imt.12.153
11. Neves AR, Ensina LF, Anselmo LB, Leite KR, Buzaid AC, Camara-Lopes LH, et al. Dendritic cells derived from metastatic cancer patients vaccinated with allogeneic dendritic cell-autologous tumor cell hybrids express more CD86 and induce higher levels of interferon-gamma in mixed lymphocyte reactions. Cancer Immunol Immunother (2005) 54:61-6. doi:10.1007/s00262-004-0550-8
12. Ramos RN, Chin LS, Dos Santos AP, Bergami-Santos PC, Laginha F, Barbuto JA. Monocyte-derived dendritic cells from breast cancer patients are biased to induce CD4+CD25+Foxp3+ regulatory T cells. J Leukoc Biol (2012) 92:673-82. doi:10.1189/jlb.0112048
13. Yi DH, Appel S. Current status and future perspectives of dendritic cell-based cancer immunotherapy. Scand J Immunol (2013) 78:167-71. doi:10.1111/sji.12060
14. Urban JL, Schreiber H. Tumor antigens. Annu Rev Immunol (1992) 10:617-44. doi:10.1146/annurev.iy.10.040192.003153
15. Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, et al. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res (2014) 20:3401-10. doi:10.1158/1078-0432.CCR-14-0433
16. Chaput N, Schartz NE, Andre F, Taieb J, Novault S, Bonnaventure P, et al. Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection. J Immunol (2004) 172:2137-46. doi:10.4049/jimmunol.172.4.2137
17. Dai S, Wei D, Wu Z, Zhou X, Wei X, Huang H, et al. Phase I clinical trial of autologous ascites-derived exosomes combined with GM-CSF for colorectal cancer. Mol Ther (2008) 16:782-90. doi:10.1038/mt.2008.1
18. Viaud S, Thery C, Ploix S, Tursz T, Lapierre V, Lantz O, et al. Dendritic cell-derived exosomes for cancer immunotherapy: what's next? Cancer Res (2010) 70:1281-5. doi:10.1158/0008-5472.CAN-09-3276
19. Zitvogel L, Regnault A, Lozier A, Wolfers J, Flament C, Tenza D, et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nat Med (1998) 4:594-600. doi:10.1038/nm0598-594
20. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, et al. B lymphocytes secrete antigen-presenting vesicles. J Exp Med (1996) 183:1161-72. doi:10.1084/jem.183.3.1161
21. Romagnoli GG, Toniolo PA, Migliori IK, Caldini ÉG, Ferreira MA, Pizzo CR, et al. Tumour cells incorporate exosomes derived from dendritic cells through a mechanism involving the tetraspanin CD9. Exosomes Microvesicles (2013) 1:4. doi:10.5772/52069
22. Hao S, Bai O, Li F, Yuan J, Laferte S, Xiang J. Mature dendritic cells pulsed with exosomes stimulate efficient cytotoxic T-lymphocyte responses and antitumour immunity. Immunology (2007) 120:90-102. doi:10.1111/j.1365-2567.2006.02483.x
23. Skogberg G, Gudmundsdottir J, van der Post S, Sandstrom K, Bruhn S, Benson M, et al. Characterization of human thymic exosomes. PLoS One (2013) 8:e67554. doi:10.1371/journal.pone.0067554
24. Suntres ZE, Smith MG, Momen-Heravi F, Hu J, Zhang X, Wu Y, et al. Therapeutic uses of exosomes. Exosomes Microvesicles (2013) 1:5. doi:10.5772/56522
25. Denzer K, van Eijk M, Kleijmeer MJ, Jakobson E, de Groot C, Geuze HJ. Follicular dendritic cells carry MHC class II-expressing microvesicles at their surface. J Immunol (2000) 165:1259-65. doi:10.4049/jimmunol.165.3.1259
26. Ludwig AK, Giebel B. Exosomes: small vesicles participating in intercellular communication. Int J Biochem Cell Biol (2012) 44:11-5. doi:10.1016/j.biocel.2011.10.005
27. Mathivanan S, Ji H, Simpson RJ. Exosomes: extracellular organelles important in intercellular communication. J Proteomics (2010) 73:1907-20. doi:10.1016/j.jprot.2010.06.006
28. Robbins PD, Morelli AE. Regulation of immune responses by extracellular vesicles. Nat Rev Immunol (2014) 14:195-208. doi:10.1038/nri3622
29. Hannafon BN, Ding WQ. Intercellular communication by exosome-derived microRNAs in cancer. Int J Mol Sci (2013) 14:14240-69. doi:10.3390/ijms140714240
30. Nolte-'t Hoen EN, Buschow SI, Anderton SM, Stoorvogel W, Wauben MH. Activated T cells recruit exosomes secreted by dendritic cells via LFA-1. Blood (2009) 113:1977-81. doi:10.1182/blood-2008-08-174094
31. Hao S, Bai O, Yuan J, Qureshi M, Xiang J. Dendritic cell-derived exosomes stimulate stronger CD8+ CTL responses and antitumor immunity than tumor cell-derived exosomes. Cell Mol Immunol (2006) 3:205-11.
32. Sprent J. Direct stimulation of naive T cells by antigen-presenting cell vesicles. Blood Cells Mol Dis (2005) 35:17-20. doi:10.1016/j.bcmd.2005.04.004
33. Viaud S, Ploix S, Lapierre V, Thery C, Commere PH, Tramalloni D, et al. Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-gamma. J Immunother (2011) 34:65-75. doi:10.1097/CJI.0b013e3181fe535b
34. McNutt M. Cancer immunotherapy. Science (2013) 342:1417. doi:10.1126/science.1249481
35. Blank CU. The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation. Curr Opin Oncol (2014) 26:204-14. doi:10.1097/CCO.0000000000000054
36. Maus MV, Grupp SA, Porter DL, June CH. Antibody-modified T cells: CARs take the front seat for hematologic malignancies. Blood (2014) 123:2625-35. doi:10.1182/blood-2013-11-492231
37. Wolfers J, Lozier A, Raposo G, Regnault A, Thery C, Masurier C, et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming. Nat Med (2001) 7:297-303. doi:10.1038/85438
38. Kourembanas S. Exosomes: vehicles of intercellular signaling, biomarkers, and vectors of cell therapy. Annu Rev Physiol (2014). doi:10.1146/annurev-physiol-021014-071641
39. Colombo M, Raposo G, Thery C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol (2014) 30:255-89. doi:10.1146/annurev-cellbio-101512-122326
40. Kooijmans SA, Vader P, van Dommelen SM, van Solinge WW, Schiffelers RM. Exosome mimetics: a novel class of drug delivery systems. Int J Nanomedicine (2012) 7:1525-41. doi:10.2147/IJN.S29661
41. Bretz NP, Ridinger J, Rupp AK, Rimbach K, Keller S, Rupp C, et al. Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via toll-like receptor signaling. J Biol Chem (2013) 288:36691-702. doi:10.1074/jbc.M113.512806
42. Barth RJ Jr, Mule JJ, Spiess PJ, Rosenberg SA. Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med (1991) 173:647-58. doi:10.1084/jem.173.3.647
43. Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and immunoediting. Immunity (2004) 21:137-48. doi:10.1016/j.immuni.2004.07.017
44. Teixeira LK, Fonseca BP, Vieira-de-Abreu A, Barboza BA, Robbs BK, Bozza PT, et al. IFN-gamma production by CD8+ T cells depends on NFAT1 transcription factor and regulates Th differentiation. J Immunol (2005) 175:5931-9. doi:10.4049/jimmunol.175.9.5931
45. Szabo SJ, Sullivan BM, Stemmann C, Satoskar AR, Sleckman BP, Glimcher LH. Distinct effects of T-bet in TH1 lineage commitment and IFN-gamma production in CD4 and CD8 T cells. Science (2002) 295:338-42. doi:10.1126/science.1065543
46. Janssen EM, Lemmens EE, Wolfe T, Christen U, von Herrath MG, Schoenberger SP. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature (2003) 421:852-6. doi:10.1038/nature01441
47. Shedlock DJ, Shen H. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science (2003) 300:337-9. doi:10.1126/science.1082305
48. Della Bella S, Gennaro M, Vaccari M, Ferraris C, Nicola S, Riva A, et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br J Cancer (2003) 89:1463-72. doi:10.1038/sj.bjc.6601243
49. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol (2004) 4:941-52. doi:10.1038/nri1498
50. Gottfried E, Kreutz M, Mackensen A. Tumor-induced modulation of dendritic cell function. Cytokine Growth Factor Rev (2008) 19:65-77. doi:10.1016/j.cytogfr.2007.10.008
51. Orsini E, Guarini A, Chiaretti S, Mauro FR, Foa R. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res (2003) 63:4497-506.